GLP-2T (5 mg/vial)
$55.00
Tirzepatide remains a 2026 bestseller as a dual GIP/GLP-1 agonist, perfect for in-depth research on glucose homeostasis, appetite control, and sustained weight reduction in preclinical settings—complementing Retatrutide for comparative metabolic studies. For research use only. Not for human or veterinary use.
30 in stock
